


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (Currently amended) A carboxylic acid amide compound of the following formula



wherein

~~one of the groups m or n denotes the number 0 and~~

~~the other group m or n denotes the number 1,~~

Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl, hydroxy, C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, whilst the phenylene group optionally substituted by a second fluorine, chlorine or bromine atom or by a second C₁₋₃-alkyl group,

~~a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C₁₋₃-alkyl group,~~

R₁ denotes a C₁₋₃-alkyl group optionally substituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl) amino, phenyl, naphthyl, heteroaryl or 4- to 7-membered cycloalkyleneimino group,

a C_{3-7} -cycloalkyl group which is substituted in the 1 position by a 5 to 7 membered cycloalkyleneimino carbonyl group;

an amino, C_{1-5} -alkylamino, C_{5-7} -cycloalkylamino or phenyl C_{1-3} -alkylamino group which may in each case be substituted at the amino nitrogen atom by a benzoyl or phenylsulphonyl group or by a C_{1-3} -alkyl or C_{1-3} -alkylcarbonyl group optionally substituted in the C_{1-3} -alkyl moiety by a carboxy group;

a 4 $\underline{5}$ to \underline{or} 7 $\underline{6}$ membered pyrrolidine or piperidine cycloalkyleneimino carbonyl or cycloalkyleneimino sulphonyl group optionally substituted by a C_{1-3} -alkyl group,

an aminosulphonyl group optionally substituted by one or two C_{1-3} -alkyl groups,

a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, aminosulphonyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,

a C_{1-3} -alkoxy, phenyl C_{1-3} -alkoxy, heteroaryloxy or heteroaryloxy C_{1-3} -alkoxy group wherein the alkoxy moiety may be substituted in the 2 or 3 position in each case by an amino, C_{1-3} -alkylamino or di-(C_{1-3} -alkyl)amino group,

a C_{3-7} -cycloalkoxy group, whilst the methylene group in the 3 or 4 position in a C_{5-7} -cycloalkoxy group may be replaced by an NH group, and said NH group may be optionally substituted

by a C_{1-3} -alkyl group which may be substituted in the 2 or 3 position by an amino, C_{1-3} -alkylamino or di-(C_{1-3} -alkyl)amino group, by a C_{1-3} -alkylcarbonyl, arylcarbonyl or arylsulphonyl group or

~~by an aminocarbonyl, C₁₋₃-alkylaminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group, wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,~~

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, hydroxy or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally substituted by a carboxy group and

R₅ denotes a cyano group or an amidino group optionally substituted by one or two C₁₋₃-alkyl groups,

said heteroaryl groups is consisting of a 5-membered heteroaryl group optionally substituted by a C₁₋₃-alkyl group which contains in the heteroaromatic moiety,

an imino group optionally substituted by a C₁₋₃-alkyl group, or an oxygen or sulphur atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,


an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or an oxygen or sulphur atom and two nitrogen atoms,

or a 6-membered heteroarylene group optionally substituted by a C₁₋₃-alkyl group which contains one or two nitrogen atoms in the heteroaromatic moiety,

the carboxy groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions or

the amino and imino groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be cleaved *in vivo*,

wherein said group which may be converted into a carboxy group is selected from the list consisting of: a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcoholic moiety preferably denotes a C₁₋₆-alkanol, a phenyl-C₁₋₃-alkanol, a C₃₋₉-cycloalkanol, whilst a C₅₋₈-cycloalkanol may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₅₋₈-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C₁₋₃-alkyl, phenyl-C₁₋₃-alkyl, phenyl-C₁₋₃-alkoxycarbonyl or C₂₋₆-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₄₋₇-cycloalkenol, a C₃₋₅-alkenol, a phenyl-C₃₋₅-alkenol, a C₃₋₅-alkynol or phenyl-C₃₋₅-alkynol, with the proviso that no bond to the oxygen atom starts from a carbon atom which carries a double or triple bond, a C₃₋₈-cycloalkyl-C₁₋₃-alkanol, a bicycloalkanol having a total of 8 to 10 carbon atoms which may additionally be substituted by one or two C₁₋₃-alkyl groups in the bicycloalkyl moiety, a 1,3-dihydro-3-oxo-1-isobenzfuranol or an alcohol of formula



and wherein

R_a denotes a C₁₋₈-alkyl, C₅₋₇-cycloalkyl, phenyl or phenyl-C₁₋₃-alkyl group,

R_b denotes a hydrogen atom, a C₁₋₃-alkyl, C₅₋₇-cycloalkyl or phenyl group and

R_c denotes a hydrogen atom or a C₁₋₃-alkyl group.

said group that is negatively charged under physiological conditions is selected from the list consisting of: a tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl, C₁₋₆-alkylsulphonylamino, phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino, C₁₋₆-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or perfluoro-C₁₋₆-alkylsulphonylaminocarbonyl group, and

said amino and imino groups are replaced by a group that may be cleaved *in vivo* selected from the group consisting of hydroxy group, an acyl group such as a benzoyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms or by C₁₋₃-alkyl or C₁₋₃-alkoxy groups, whilst the substituents may be identical or different, a pyridinoyl group or a C₁₋₁₆-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C₁₋₁₆-alkoxycarbonyl or C₁₋₁₆-alkylcarbonyloxy group wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms, such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert. butoxycarbonyl, pentoxy carbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert. butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C₁₋₆-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group wherein the amino group may be mono or disubstituted by C₁₋₆-alkyl or C₃₋₇-cycloalkyl groups and the substituents may be identical or different, a C₁₋₃-alkylsulphonyl-C₂₋₄-alkoxycarbonyl, C₁₋₃-alkoxy-C₂₋₄-alkoxy-C₂₋₄-alkoxycarbonyl, R_a-CO-O-(R_bCR_c)-O-CO, C₁₋₆-alkyl-CO-NH-(R_dCR_e)-O-CO or C₁₋₆-alkyl-CO-O-(R_dCR_e)-(R_dCR_e)-O-CO group wherein R_a to R_e are as hereinbefore defined,

R_d and R_e, which may be identical or different, denote hydrogen atoms or C₁₋₃-alkyl groups,

an isomer or salt thereof.

2. (Currently amended) The compound of formula I according to claim 1 wherein

~~one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,~~

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a methyl, hydroxy, methoxy or benzyloxy group, which may be substituted by another methyl group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group;

~~a methyl group substituted by a dimethylamino, pyrrolidino or imidazolyl group, wherein the imidazolyl moiety may be substituted by a methyl group,~~

~~an amino, C₁₋₅-alkylamino, cyclopentylamino or benzylamino group which may be substituted at the amino nitrogen atom by a carboxy-C₁₋₂-alkyl, C₁₋₃-alkoxycarbonyl-C₁₋₂-alkyl, carboxy-C₁₋₂-alkylcarbonyl or C₁₋₃-alkoxycarbonyl-C₁₋₂-alkylcarbonyl group,~~

~~a benzoylamino or phenylsulphonylamino group,~~

~~a cyclopropyl group which is substituted in the 1 position by a 5 to 7 membered cycloalkyleneiminocarbonyl group,~~

~~an optionally methyl-substituted pyrrolidinocarbonyl, or piperidinocarbonyl, pyrrolidinesulphonyl or piperidinesulphonyl group,~~

a C_{1-3} -alkoxy group wherein the alkoxy moiety in the 2 or 3 position may be substituted in each case by an amino, C_{1-3} -alkylamino or di (C_{1-3} -alkyl) amino group;

a phenyl C_{1-3} -alkoxy or pyridinyloxy group;

a C_{5-7} -cycloalkoxy group wherein the methylene group in the 3 or 4 position may be replaced by an NH group, whilst the NH group may be substituted

by a C_{1-3} -alkyl or C_{2-3} -alkanoyl group;

by a C_{2-3} -alkanoyl or aminocarbonyl group wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group;

R_2 denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, hydroxy or methoxy group,

R_3 denotes a hydrogen atom or a methyl group,

R_4 denotes a hydrogen atom or a methyl or ethyl group optionally substituted by a carboxy or C_{1-3} -alkoxycarbonyl group and

R_5 denotes a cyano group or an amidino group optionally substituted by a C_{1-6} -alkoxycarbonyl or benzoyl group,

or an isomers or salt thereof.

3. (Currently amended) The compounds of formula I according to claim 1, wherein

one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a methyl, hydroxy, methoxy or benzyloxy group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a cyclopropyl group which is substituted in the 1 position by a 5 to 7 membered cycloalkyleneiminocarbonyl group, or a 4 to 7 membered cycloalkyleneiminocarbonyl group;

an optionally methyl-substituted pyrrolidinocarbonyl, or piperidinocarbonyl or pyrrolidinesulphonyl group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom or a methyl group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group substituted by a carboxy, methoxycarbonyl or ethoxycarbonyl group and

R₅ denotes an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

or an isomer or salt thereof.

4. (Currently amended) A compound of the formula I according to claim 1 selected from the following compounds:

(a) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(b) 2-(3-carbamimidoyl-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(c) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-methyl-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(d) 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-methyl-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(e) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(N-(3-ethoxycarbonyl-propionyl)-N-cyclopentyl-amino)-phenyl]-acetamide,

(f) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(g) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide,

(h) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-methyl-pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(bi) 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(ej) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonylethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide; and

(dk) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(e) ~~2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide and~~

(f) ~~2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide,~~

wherein the amidino group may additionally be substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group, and the salts thereof.

5. (Previously amended) A compound of formula I according to claim 1 as follows:
2-(5-Carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and the salts thereof.

6.. (Previously amended) A pharmaceutical composition comprising a compound according to claim 1 or a physiologically acceptable salt thereof according to claims 1 wherein R₅ is an amidino group optionally substituted by one or two C₁₋₃-alkyl groups.

7. (Previously amended) Pharmaceutical compositions containing a compound according to claim 1, wherein R₅ is an amidino group optionally substituted by one or two C₁₋₃-alkyl groups.

8. (Previously amended) A method of treating a patient in need of a pharmaceutical composition having an antithrombotic activity or factor Xa inhibiting activity by administering to said patient a therapeutically effective amount of a component according to claim 1 wherein R₅ is an amidino group optionally substituted by one or two C₁₋₃-alkyl groups.

9. (Previously cancelled)

10. (Previously cancelled)

11. (Cancelled)

12. (Cancelled)

13.(Previously amended) A method of treating a patient in need of a pharmaceutical composition having an antithrombotic activity or factor Xa inhibiting activity by administering to said patient a therapeutically effective amount of a component according to claim 6.

14. (Previously amended) Pharmaceutical compositions containing a compound according to a salt of claim 6 optionally together with one or more inert carriers and/or diluents.

15. (Cancelled)

16. (Cancelled)

17. (New) A compound of the formula I according to claim 1 selected from the following compounds:

(a) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(b) 2-(3-carbamimidoyl-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(c) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-methyl-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(d) 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-methyl-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(e) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(N-(3-ethoxycarbonyl-propionyl)-N-cyclopentyl-amino)-phenyl]-acetamide,

(f) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(g) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide and

(h) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-methyl-pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(i) 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(j) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonylethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(k) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(l) 2-[5-(N-benzoyl-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(m) 2-[5-(N-n-hexyloxycarbonyl-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(n) 2-[5-(N-benzoyl-carbamimidoyl)-2-methoxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(o) 2-[5-(N-n-hexyloxycarbonyl-carbamimidoyl)-2-methoxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(p) 2-[5-(N-ethyloxycarbonyl-carbamimidoyl)-2-methoxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide.

(q) 2-[5-(N-hydroxy-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(r) 2-[5-(N-hydroxy-carbamimidoyl)-2-methoxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

an isomer or salt thereof.